<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>U10e IPR on eMeets - Slow Long Knowledge</title><link>https://www.doccentre.in/emeets/u10e-ipr/</link><description>Recent content in U10e IPR on eMeets - Slow Long Knowledge</description><generator>Hugo</generator><language>en</language><lastBuildDate>Mon, 04 Jul 2022 02:18:16 +0000</lastBuildDate><atom:link href="https://www.doccentre.in/emeets/u10e-ipr/index.xml" rel="self" type="application/rss+xml"/><item><title>The WTO faces a make or break week over vaccines</title><link>https://www.doccentre.in/emeets/u10e-ipr/the-wto-faces-a-make-or-break-week-over-vaccines/</link><pubDate>Mon, 04 Jul 2022 02:18:16 +0000</pubDate><guid>https://www.doccentre.in/emeets/u10e-ipr/the-wto-faces-a-make-or-break-week-over-vaccines/</guid><description>&lt;p&gt;The WTO faces a make or break week over vaccines by Larry Elliott &lt;a href="https://www.theguardian.com/business/2022/jun/12/the-wto-faces-a-make-or-break-week-over-vaccines"&gt;https://www.theguardian.com/business/2022/jun/12/the-wto-faces-a-make-or-break-week-over-vaccines&lt;/a&gt;  &lt;/p&gt;&#13;&#10;&lt;p&gt;Richer countries make all the right noises about the need to share the benefits of the breakthroughs made to fight Covid-19, but in practice they have been dragging their heels in talks for the past two years. Switzerland, the EU, the UK and the US – all of which have strong and powerful pharmaceutical sectors – have tried to make any waiver to TRIPS (trade related intellectual property rights) as weak and as time-limited as possible.&lt;/p&gt;</description></item></channel></rss>